{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:17:55Z","timestamp":1787699875055,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014735","name":"Royal College of Physicians and Surgeons of Canada","doi-asserted-by":"publisher","award":["2025 Detweiler Travelling Fellowship"],"award-info":[{"award-number":["2025 Detweiler Travelling Fellowship"]}],"id":[{"id":"10.13039\/100014735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009195","name":"Department of Medicine, Ottawa Hospital","doi-asserted-by":"publisher","award":["Department of Medicine Academic Scholarship Program"],"award-info":[{"award-number":["Department of Medicine Academic Scholarship Program"]}],"id":[{"id":"10.13039\/501100009195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06218-1","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:23:52Z","timestamp":1781637832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful corticosteroid-free management of anti-HMG\u2013CoA reductase immune-mediated necrotizing myopathy with subcutaneous immunoglobulins monotherapy: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2270-4708","authenticated-orcid":false,"given":"Nikola","family":"Wilk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthaporn","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Warman-Chardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ivory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"6","key":"6218_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/imj.15358","volume":"51","author":"C Ashton","year":"2021","unstructured":"Ashton C, et al. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021;51(6):845\u201352.","journal-title":"Intern Med J"},{"issue":"27","key":"6218_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"2","key":"6218_CR3","volume":"12","author":"A Patwardhan","year":"2020","unstructured":"Patwardhan A. The value of intravenous immunoglobulin therapy in idiopathic inflammatory myositis in the current transformed era of biologics. Cureus. 2020;12(2): e7049.","journal-title":"Cureus"},{"issue":"12","key":"6218_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","volume":"13","author":"MG Danieli","year":"2014","unstructured":"Danieli MG, et al. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev. 2014;13(12):1182\u20138.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"6218_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/rheumatology\/keu429","volume":"54","author":"B Mulhearn","year":"2015","unstructured":"Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015;54(3):383\u201391.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"6218_CR6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMc1214823","volume":"368","author":"EW Gelfand","year":"2013","unstructured":"Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2013;368(8):777.","journal-title":"N Engl J Med"},{"key":"6218_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.893770","volume":"10","author":"G Solis-Diez","year":"2022","unstructured":"Solis-Diez G, et al. Dealing with immunoglobulin shortages: a rationalization plan from evidence-based and data collection. Front Public Health. 2022;10: 893770.","journal-title":"Front Public Health"},{"key":"6218_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7547-8-14","volume":"8","author":"G Blackhouse","year":"2010","unstructured":"Blackhouse G, et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14.","journal-title":"Cost Eff Resour Alloc"},{"key":"6218_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"issue":"3","key":"6218_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173\u201384.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"6218_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94\u2013100.","journal-title":"J Clin Immunol"},{"issue":"2","key":"6218_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ene.13218","volume":"24","author":"LH Markvardsen","year":"2017","unstructured":"Markvardsen LH, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol. 2017;24(2):412\u20138.","journal-title":"Eur J Neurol"},{"issue":"1","key":"6218_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/24725625.2020.1782031","volume":"5","author":"VP Mak","year":"2021","unstructured":"Mak VP, Gravely K, Lim SY. Subcutaneous immunoglobulin therapy in statin-induced necrotizing autoimmune myopathy. Mod Rheumatol Case Rep. 2021;5(1):58\u201361.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"6218_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nmd.2020.12.012","volume":"31","author":"A Zuppa","year":"2021","unstructured":"Zuppa A, et al. Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy. Neuromuscul Disord. 2021;31(2):134\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"6218_CR15","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/brain\/awq270","volume":"133","author":"A Compston","year":"2010","unstructured":"Compston A. Aids to the investigation of peripheral nerve injuries. Medical research council: nerve injuries research committee. His Majesty\u2019s stationery office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O\u2019Brien for the guarantors of brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 figures. Brain. 2010;133(10):2838\u201344.","journal-title":"Brain"},{"issue":"1","key":"6218_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, et al. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord. 2018;28(1):87\u201399.","journal-title":"Neuromuscul Disord"},{"issue":"17","key":"6218_CR17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680\u20132.","journal-title":"N Engl J Med"},{"issue":"3","key":"6218_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","volume":"15","author":"P Cherin","year":"2016","unstructured":"Cherin P, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases. Autoimmun Rev. 2016;15(3):281\u20136.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"6218_CR19","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd AGS, et al. British society for rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology. 2022;61(5):1760\u20138.","journal-title":"Rheumatology"},{"issue":"1","key":"6218_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5114\/reum.2022.114108","volume":"60","author":"MKR Somagutta","year":"2022","unstructured":"Somagutta MKR, et al. Statin-induced necrotizing autoimmune myopathy: a systematic review. Reumatologia. 2022;60(1):63\u20139.","journal-title":"Reumatologia"},{"issue":"3","key":"6218_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaccas.2019.12.019","volume":"2","author":"B Gawey","year":"2020","unstructured":"Gawey B, et al. Statin-induced necrotizing autoimmune myopathy. JACC Case Rep. 2020;2(3):440\u20133.","journal-title":"JACC Case Rep"},{"issue":"9","key":"6218_CR22","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1093\/rheumatology\/keaf238","volume":"64","author":"T Khoo","year":"2025","unstructured":"Khoo T, et al. The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. Rheumatology. 2025;64(9):4995\u20135003.","journal-title":"Rheumatology"},{"issue":"11","key":"6218_CR23","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.3390\/jcm9113454","volume":"9","author":"E Treppo","year":"2020","unstructured":"Treppo E, et al. Efficacy and safety of high-dose immunoglobulin-based regimen in statin-associated autoimmune myopathy: a multi-center and multi-disciplinary retrospective study. J Clin Med. 2020;9(11):3454.","journal-title":"J Clin Med"},{"issue":"3","key":"6218_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/mus.28333","volume":"71","author":"J Suh","year":"2025","unstructured":"Suh J, Amato AA. Effectiveness and safety of IVIG for the treatment of HMGCR immune-mediated necrotizing myopathy. Muscle Nerve. 2025;71(3):392\u20137.","journal-title":"Muscle Nerve"},{"issue":"1","key":"6218_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13023-022-02570-9","volume":"17","author":"T Namsrai","year":"2022","unstructured":"Namsrai T, et al. Diagnostic delay of myositis: an integrated systematic review. Orphanet J Rare Dis. 2022;17(1):420.","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"6218_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734\u201347.","journal-title":"N Engl J Med"},{"issue":"4","key":"6218_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","volume":"33","author":"MG Danieli","year":"2014","unstructured":"Danieli MG, et al. Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol. 2014;33(4):531\u20136.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"6218_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/00207454.2016.1204544","volume":"127","author":"E Hachulla","year":"2017","unstructured":"Hachulla E, et al. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Int J Neurosci. 2017;127(6):516\u201323.","journal-title":"Int J Neurosci"},{"key":"6218_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab070","author":"AL Zhou","year":"2021","unstructured":"Zhou AL, Maltez N, Ivory C. Use of subcutaneous immunoglobulin in inflammatory myositis. Rheumatol Adv Pract. 2021. https:\/\/doi.org\/10.1093\/rap\/rkab070.","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"6218_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1573397113666170314120602","volume":"14","author":"MG Danieli","year":"2018","unstructured":"Danieli MG, et al. Subcutaneous IgG in the myositis spectrum disorders. Curr Rheumatol Rev. 2018;14(3):194\u20139.","journal-title":"Curr Rheumatol Rev"},{"issue":"1","key":"6218_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","volume":"22","author":"A Meyer","year":"2020","unstructured":"Meyer A, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020;22(1):5.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6218_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"2","key":"6218_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","volume":"120","author":"LW Fu","year":"2018","unstructured":"Fu LW, et al. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis. Ann Allergy Asthma Immunol. 2018;120(2):195\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"6218_CR34","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1093\/rheumatology\/kead521","volume":"63","author":"Z Ma","year":"2024","unstructured":"Ma Z, Johnson D, Gniadecki R, Ritchie B, Keeling S, Cohen Tervaert JW, Osman M. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience. Rheumatology. 2024;63(8):2118\u201322.","journal-title":"Rheumatology"},{"issue":"3","key":"6218_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli MG, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev. 2011;10(3):144\u20139.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"6218_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141616","volume":"10","author":"Y Ge","year":"2015","unstructured":"Ge Y, et al. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme a reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS ONE. 2015;10(10): e0141616.","journal-title":"PLoS ONE"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06218-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:42:03Z","timestamp":1787697723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06218-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6218"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06218-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this single case report, in accordance with the Ottawa Hospital Research Institute for Ottawa Health Science Network Research Ethics Board policy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest. JC received consultation fees or honorarium for educational presentations from Takeda, CSL Behring. JC is the medical lead for the Ontario Immunoglobulin Treatment program funded by the Ministry of Health, Government of Ontario.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"496"}}